Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany.
Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany.
Obes Res Clin Pract. 2024 Mar-Apr;18(2):81-87. doi: 10.1016/j.orcp.2024.03.007. Epub 2024 Apr 6.
The BMI predicts mortality and cardiovascular disease (CVD) in the general population, while in patients with end-stage chronic kidney disease (CKD) a high BMI is associated with improved survival, a phenomenon referred to as the "obesity paradox". While BMI is easy to determine and helps to categorize patients, it does not differentiate between fat tissue, lean tissue and bone mass. As the BMI may be altered in CKD, e.g. by muscle wasting, we determined in this meta-analysis (i) the association of mortality with fat tissue quantity in CKD and (ii) the association of mortality with abdominal obesity (as measured by waist circumference (WC) or waist-to-hip ratio (WHR)) in CKD. We systematically reviewed databases for prospective or retrospective cohort studies. In eleven studies with 23,523 patients the association between mortality and high fat tissue quantity in CKD was calculated. The pooled hazard ratio (HR) for this association in the CKD group in the dialysis group 0.91 (CI 0.84- 0.98, p = 0.01) which is comparable to the HR for the association with BMI. The HR in patients without dialysis was 0.7 (95% CI 0.53- 0.93, p = 0.01), suggesting a better risk prediction of high fat tissue content with mortality as compared to higher BMI with mortality in patients with CKD without dialysis. Importantly, both BMI and fat tissue quantity in CKD are described by the "obesity paradox": the higher the fat tissue content or BMI, the lower the mortality risk. In thirteen studies with 55,175 patients the association between mortality and high WC or WHR in CKD (with or without dialysis) was calculated. We observed, that the HR in the WHR group was 1.31 (CI 1.08-1.58, p = 0.007), whereas the overall hazard ratio of both groups was 1.09 (CI 1.01-1.18, p = 0.03), indicating that a higher abdominal obesity as measured by WHR is associated with higher mortality in CKD. Our analysis suggests gender-specific differences, which need larger study numbers for validation. This meta-analysis confirms the obesity paradox in CKD using fat tissue quantity as measure and further shows that using abdominal obesity measurements in the routine in obese CKD patients might allow better risk assessment than using BMI or fat tissue quantity. Comparable to the overall population, here, the higher the WHR, the higher the mortality risk.
体重指数(BMI)可预测普通人群的死亡率和心血管疾病(CVD),而在终末期慢性肾脏病(CKD)患者中,高 BMI 与生存率提高相关,这种现象被称为“肥胖悖论”。虽然 BMI 易于确定并有助于对患者进行分类,但它不能区分脂肪组织、瘦组织和骨量。由于 CKD 患者的 BMI 可能发生改变,例如肌肉消耗,因此我们在这项荟萃分析中确定了(i)CKD 患者的死亡率与脂肪组织量之间的关系,以及(ii)CKD 患者的死亡率与腹型肥胖(通过腰围(WC)或腰臀比(WHR)测量)之间的关系。我们系统地回顾了前瞻性或回顾性队列研究的数据库。在 11 项纳入 23523 名患者的研究中,计算了死亡率与 CKD 患者脂肪组织量之间的相关性。在透析组中,该相关性的合并危险比(HR)为 0.91(95%CI 0.84-0.98,p=0.01),与 BMI 相关的 HR 相当。未接受透析的患者的 HR 为 0.7(95%CI 0.53-0.93,p=0.01),这表明与死亡率相关的高 BMI 相比,高脂肪组织含量对死亡率的风险预测更好。重要的是,CKD 中的 BMI 和脂肪组织量均受“肥胖悖论”的影响:脂肪组织含量或 BMI 越高,死亡率风险越低。在纳入 55175 名患者的 13 项研究中,计算了死亡率与 CKD(无论是否透析)患者高 WC 或 WHR 之间的相关性。我们观察到,WHR 组的 HR 为 1.31(95%CI 1.08-1.58,p=0.007),而两组的总体危险比为 1.09(95%CI 1.01-1.18,p=0.03),这表明通过 WHR 测量的更高的腹型肥胖与 CKD 患者的更高死亡率相关。我们的分析表明存在性别特异性差异,需要更大的研究数量来验证。这项荟萃分析使用脂肪组织量作为测量指标,证实了 CKD 中的肥胖悖论,并进一步表明,在肥胖的 CKD 患者中,常规使用腹部肥胖测量可能比使用 BMI 或脂肪组织量进行风险评估更好。与总体人群一样,这里的 WHR 越高,死亡率风险越高。